Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for CAMP4 Therapeutics Corporation (CAMP : NSDQ)
 
 • Company Description   
CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases. CAMP4 Therapeutics Corporation is based in CAMBRIDGE, Mass.

Number of Employees: 55

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.43 Daily Weekly Monthly
20 Day Moving Average: 128,816 shares
Shares Outstanding: 20.16 (millions)
Market Capitalization: $28.83 (millions)
Beta:
52 Week High: $12.30
52 Week Low: $1.31
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -23.12% -27.28%
12 Week -31.91% -42.87%
Year To Date -72.61% -74.34%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
ONE KENDALL SQUARE BUILDING 1400 WEST 3RD FLOOR
-
CAMBRIDGE,MA 02139
USA
ph: 617-651-8867
fax: -
svonderweid@lifesciadvisors.com http://www.camp4tx.com
 
 • General Corporate Information   
Officers
Josh Mandel-Brehm - Chief Executive Officer and President
Steven Holtzman - Chairman
Kelly Gold - Chief Financial Officer
James Boylan - Director
Ingo Chakravarty - Director

Peer Information
CAMP4 Therapeutics Corporation (CORR.)
CAMP4 Therapeutics Corporation (RSPI)
CAMP4 Therapeutics Corporation (CGXP)
CAMP4 Therapeutics Corporation (BGEN)
CAMP4 Therapeutics Corporation (GTBP)
CAMP4 Therapeutics Corporation (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 13463J101
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/12/25
Share - Related Items
Shares Outstanding: 20.16
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $28.83 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.68 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.48 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/12/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.56
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -
12/31/24 - -
ROA
06/30/25 - -
03/31/25 - -
12/31/24 - -
Current Ratio
06/30/25 - -
03/31/25 - 8.02
12/31/24 - 6.92
Quick Ratio
06/30/25 - -
03/31/25 - 8.02
12/31/24 - 6.92
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -7,943.40
Book Value
06/30/25 - -
03/31/25 - 2.56
12/31/24 - 3.13
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.11
12/31/24 - 0.11
 

Powered by Zacks Investment Research ©